Abstract
Slow transit constipation (STC) is a type of functional constipation resulting from a lack of intestinal motility. The primary symptoms are challenging defecation and desiccated feces, which may readily result in perianal, cardiovascular, cerebrovascular, and psychological disorders. The structural and morphological impairment of the enteric nervous system (ENS), along with the dysfunction of interstitial cells of Cajal (ICCs) and smooth muscle cells (SMCs), are the primary contributors to the onset and progression of STC. In recent years, traditional Chinese medicine (TCM) has emerged as an alternative for the therapeutic prevention and treatment of STC. Metabolites obtained from botanical drugs, including quercetin and nobiletin, may ameliorate symptoms of STC, presenting a possible therapeutic approach for STC. This review summarizes metabolites derived from botanical drugs, including flavonoids, terpenoids, steroids, polysaccharides, anthraquinones, and phenylpropanoids, emphasizing their regulatory mechanisms in the treatment of STC via the ENS-ICC-SMC pathway, while also addressing future challenges and developmental directions.
1 Introduction
Slow transit constipation (STC) is a refractory form of constipation occurring from numerous non-organic causes of colonic motility problems, leading to delayed passage of intestinal contents. STC mainly presented with difficult defecation, dry stool, abdominal pain and distension (). The worldwide prevalence of STC is 14%, whereas among the senior population, it may attain 18% (; ). Laxatives and surgical intervention are prevalent therapies for restoring intestinal motility in patients with STC; however, they are associated with complications including electrolyte imbalance, intestinal mucosal discoloration, postoperative abdominal pain, intestinal obstruction, and recurrence, all of which significantly diminish patients’ quality of life (). Impaired gastrointestinal peristalsis due to intestinal motility disorder is the primary factor contributing to the onset and progression of STC, whereas the enteric nervous system (ENS), interstitial cells of Cajal (ICCs), and smooth muscle cells (SMCs) are essential for sustaining normal gastrointestinal motility (; ; ).
The ENS is an extensive and intricate network of ganglionic plexuses composed of neurons, nerve fibers, and glial cells situated within the stomach wall (; ). The ENS can elicit reflex intestinal contractions without central nervous system (CNS) involvement and can autonomously regulate gastrointestinal motility and secretory processes (). Neurotransmitters released by neurons in the ENS constitute the fundamental basis for the regulation of gastrointestinal function. This includes excitatory neurotransmitters such as acetylcholine (ACh) and Substance P (SP), inhibitory neurotransmitters like vasoactive intestinal peptide (VIP) and nitric oxide (NO), as well as bidirectional neurotransmitters such as 5-hydroxytryptamine (5-HT), all of which collectively influence gastrointestinal motility (; ). Nonetheless, the ENS does not directly convey signals to the SMCs; rather, there exists an intermediary signal transmission medium, specifically ICCs. Within the gastrointestinal tract, ICCs are situated adjacent to the myenteric nerve plexus and gastrointestinal motor neurons, establishing synaptic connections with nerve terminals. They transfer both excitatory and inhibitory signals to SMCs via gap junctions, resulting in the relaxation and contraction of SMCs (). Furthermore, ICCs can generate slow waves and transmit them to SMCs, together governing intestinal contraction and peristalsis (). Simultaneously, injury to SMCs, as the ultimate regulators of intestinal motility, will immediately result in diminished intestinal peristalsis and the development of STC (). The ENS-ICC-SMC pathway indicates that neuronal decrease and dysfunction, neurotransmitter imbalance, morphological alterations in ICCs, and injury to SMCs can precipitate the onset of STC. Consequently, identifying alternate techniques and pharmacological agents to enhance STC by modulating the ENS-ICC-SMC pathway is a critical issue that requires resolution.
Prior research indicates that metabolites of botanical drugs can markedly alleviate symptoms of STC by modulating neurotransmitter levels, including serotonin (5-HT) and vasoactive intestinal peptide (VIP), within the compromised ENS, as well as neurotrophic factors such as glial-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF) (; ), while also facilitating the repair of damaged ICCs and SMCs (). This review will offer a thorough examination of in vivo and in vitro tests and outline the research advancements on the metabolites from botanical drugs in enhancing STC via the ENS-ICC-SMC pathway (Table 1).
TABLE 1
| Metabolites | Test subject | Dosage of drugs | The medication time | Control drugs | Mechanism | Site of action | Ref. |
|---|---|---|---|---|---|---|---|
| Quercetin | Rats | Gavage of aqueous solution (10, 25, 50 mg/kg) | 24 h | — | Upregulation: MTL, Gas, AchE, SP, c-Kit, SCF, GDNF Downregulation: SS, TRPV1, NOS. | ICC, Neurotransmitters | |
| Nobiletin | Rats | Gavage of aqueous solution (10, 20, 40 mg/kg) | 14 days | Mosapride (2.5 mg/kg) | Upregulation: c-kit, SCF Downregulation: 5-HT, VIP, NO, NOS. | ICC, Neurotransmitters | |
| Nobiletin | Mouse, Primary ICCs | Gavage of aqueous solution (100, 300 mg/kg) | 70 days | Mosapride (2.5 mg/kg) | Upregulation: Ki-67, PCNA, Bcl2 Downregulation: MAPT, TNF-α, IL-1β, IL-6, IFN-γ, P38, JNK, ERK, NF-κB p65, Bax Inhibit MAPK pathway | ICC, Neurotransmitters | |
| Hesperidin | Rats | Gavage of aqueous solution (50,100,200 mg/kg) | 7 days | Macrogol 4,000 Powder (0.9 g/kg) | Upregulation: 5-HT, 5-HT4R, PGP9.5, PDGFRα, ANO1, P2Y1, c-kit, SK3 | ENS, ICC, SMC, Neurotransmitters | |
| Hesperidin | Rats, Primary smooth muscle cells | Gavage of aqueous solution (50,100,200 mg/kg) | 14 days | — | Upregulation: 5-HTR4, Ca2+, ADCY3, cAMP, PKA, CREB, p-CREB Activate the cAMP/PKA、p-CREB pathway | SMC | |
| Naringenin | Mouse | Gavage of aqueous solution (70, 150, 300 mg/kg) | 5 days | — | Upregulation: MTL, Gas, ET, SP, AChE, GDNF, BDNF, c-Kit, SCF Downregulation: TRPV1, NOS. | ENS, ICC, Neurotransmitters | |
| Paeoniflorin | Rats | Gavage of aqueous solution (40 mg/kg) | 14 days | lactulose oral solution (3.5 mL/kg) | Upregulation: 5-HT, ASIC3, p-ERK/ERK Downregulation: VIP Activate the ASIC3/ERK pathway | Neurotransmitters | |
| Paeoniflorin | Rats, RIN-14B cell | Gavage of aqueous solution (10, 20, 40 mg/kg); Medium solution (20, 40, 80 μg/mL) | 14 days; 24 h | — | Upregulation: 5-HT, Tph-1, TGR5, TRPA1, PLC-γ1, PIP2 Activate the TGR5/TRPA1 pathway | Neurotransmitters | |
| Astragaloside IV | Mouse, QGP-1 cell | Gavage of aqueous solution (30 mg/kg); Medium solution (50 μm) | 5 days; 24 h | — | Upregulation: CD117, CgA, TPH1, Piezo2, p-p38, p-ERK, Caspase-3, Bcl-2 Downregulation: Caspase-3 p12, Bax Inhibit p38 MAPK and ERK pathways | ICC, ENS | |
| Astragaloside IV | Mouse, Primary ICCs | Gavage of aqueous solution (10, 30, 90 mg/kg) | 5 days | — | Upregulation: c-Kit, p-P65/P65, pAKT/AKT Activate the AKT/NF-κB pathway | ICC | |
| Pulsatilla saponin A | Rats | Gavage of aqueous solution (100, 150, 300 mg/kg) | 14 days | — | Upregulation: 5-HT, c-kit, SCF Downregulation: VIP, NO Activate the c-kit/SCF pathway | ICC, Neurotransmitters | |
| β-sitosterol | Mouse | Gavage of aqueous solution (200, 500, 750 mg/kg) | 7 days | phenolphthalein tablet (200 mg/mL) | Upregulation: ADRA1A, Myl9, smMLCK, 5-HTR4, 5-HT, AchE, c-Kit, SCF Activate the ADRA1A-MLC pathway | ICC, SMC, Neurotransmitters | |
| Dioscin | Mouse | Gavage of aqueous solution (60 mg/kg) | 7 days | — | Upregulation: BMP2, p-Smad 1/5/9, HuC/D+, AchE Downregulation: iNOS, IL-6, TNF-α, VIP Activate the BMP2/p-Smad1/5/9 pathway | ENS, Neurotransmitters | |
| Spicatoside A | Mouse | Gavage of aqueous solution (20 mg/kg) | 7 days | — | Upregulation: AChE, IP3, C-kit, PGP9.5 Downregulation: Bax, Bcl2, CD34, Gα, p-PKC/PKC, p-PI3K/PI3K, p-MLC/MLC. | ENS, ICC, SMC, Neurotransmitters | |
| Lycium barbarum polysaccharide | Rats | Gavage of aqueous solution (40, 80, 120 mg/kg) | 14 days | Mosapride (2.5 mg/kg) | Upregulation: SP, C-kit, SCF, Bcl-2 Downregulation: VIP, Bax, Caspase-3 | ICC, Neurotransmitters | |
| Cistanche deserticola crude polysaccharides | Mouse | Gavage of aqueous solution (100, 200, 400 mg/kg) | 7 days | — | Upregulation: SP, SOD, GSH, HuC/D+, Nrf2, HO-1, NQO1, GCLC, GCLM Downregulation: VIP, MDA, Keap1 Activate the Nrf2/Keap1 pathway | ENS, Neurotransmitters | |
| Emodin | Mouse | Gavage of aqueous solution (50 mg/kg) | 7 days | — | Upregulation: 5-HTR4, GDNF, BDNF, c-Kit, SCF Downregulation: NO, VIPR1, TRPV 1, NOS. | ENS, ICC, Neurotransmitters | |
| Sennoside A | Rats, Smooth muscle strips | Gavage of aqueous solution (1 mg/kg) | 30 min | — | Upregulation: SP, MOT Downregulation: VIP, CGRP Activate HCN1 channel on ICC membrane | ICC, Neurotransmitters | |
| Cinnamic acid | Rats | Gavage of aqueous solution (40, 80 mg/kg) | 28 days | Prucalopride (0.26 mg/kg) | Upregulation: 5-HT Downregulation: VIP. | Neurotransmitters | |
| Total glucosides of paeony | Rats | Gavage of aqueous solution (0.18 g/kg) | 14 days | — | UpregulationSP. Downregulation: NO, NOS, VIP. | ICC, Neurotransmitters | |
| Pterostilbene | Mouse | 0.5% carboxymethylcellulose sodium solution by gavage (30, 60 mg/kg) | 7 days | — | Upregulation: c-kit, SCF, GSH-Px, p-AKT/AKT, Nrf2, HO-1 Downregulation: caspase-3, MDA Regulates the PI3K/AKT and Nrf2/HO-1 pathways | ICC |
Metabolites from botanical drugs modulate STC by influencing the ENS-ICC-SMC pathway.
2 Methods of data acquisition
The original articles included in this study were sourced from the PubMed, Web of Science, and CNKI databases. The search terms comprised “slow transit constipation,” “traditional Chinese medicine,” “metabolites from botanical drugs,” “pharmacology,” “enteric nervous system,” “interstitial cells of Cajal,” “smooth muscle cells,” “neurotransmitter,” and their permutations. The search concluded on 1 March 2025, with no prior time constraints imposed. The criteria for inclusion and exclusion were as follows: 1) The pharmacological mechanisms of metabolites from botanical medications in the treatment of STC; 2) The metabolites demonstrate anti-STC actions via the ENS, ICCs, or SMCs; studies unrelated to the ENS-ICC-SMC pathway were omitted. In the screening process, we first examined titles and abstracts to find pertinent research that satisfied the inclusion criteria, followed by an analysis of full-text publications for comprehensive evaluation, culminating in the inclusion of 21 articles.
3 Metabolites classification
3.1 Flavonoids
Flavonoids constitute a category of metabolites characterized by a fundamental C6-C3-C6 backbone and a core structure of 2-phenylchromogen (). Flavonoids are prevalent in botanical drugs, fruits, and vegetables, exhibiting diverse pharmacological actions, including anti-inflammatory () and antioxidative stress properties (). Quercetin is one of the metabolites of Ginkgo folium (Ginkgo biloba L.) and Scutellariae radix (Scutellaria baicalensis Georgi). Researchers developed a rat model of constipation using loperamide to assess the therapeutic efficacy of quercetin. The findings indicated that quercetin enhanced intestinal transport rate, elevated serum motilin (MTL), gastrin (Gas), acetylcholine esterase (AchE), and SP levels, while reducing somatostatin (SS) expression in constipated rats. Simultaneously, quercetin can upregulate the mRNA of c-kit proto-oncogene protein (c-Kit), stem cell factor (SCF), and GDNF in the intestinal tissue of constipated rats, while downregulating the expression of transient receptor potential vanilloid 1 (TRPV1) and nitric oxide synthase (NOS) (). Nobiletin, a flavonoid derived from the pericarp of Citri reticulatae (Citrus reticulata Blanco), exhibits antifungal and anti-inflammatory properties. Nobeletin enhances the amplitude of slow wave frequency in colon electromyography in STC mice, diminishes the levels of 5-HT, NO, and NOS in colon tissue, and elevates the protein expression of c-kit and SCF, which are markers for ICCs in the colon (). Nobiletin diminished the expression of microtubule-associated protein-tau (MAPT) in colon tissue and decreased the levels of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), interferon-γ (IFN-γ), and mitogen-activated protein kinase (MAPK) pathway-related proteins in the serum of STC mice. Nobiletin can inhibit the apoptosis of ICCs in vitro, which is related to the inhibition of MAPT expression and the activation of MAPK pathway in ICCs of STC mice (). Hesperidin and naringenin, metabolites obtained from Aurantii fructus and Aurantii fructus immaturus (Citrus aurantium L.), exhibit notable therapeutic effects on STC. Hesperidin can restore colonic motility and the morphology of damaged colonic tissue in STC rats, potentially by activating the 5-HT signaling pathway, upregulating the expression of anoctamin 1 (ANO1), c-kit, platelet-derived growth factor receptor α (PDGFRα), P2Y purinoceptor 1 (P2Y1), and KCa2.3 (SK3), thereby restoring the phenotype and function of ICCs and PDGFRα+ cells, and enhancing SIP syncytia function (). Moreover, hesperidin can rehabilitate the gastrointestinal transmission function in STC rats, augment the quantity of colonic SMCs and neurons, and stimulate the proliferation of SMCs in vitro, potentially linked to the upregulation of the 5-Hydroxytryptamine receptor 4 (5-HTR4) and intracellular calcium ion concentration. Furthermore, the upregulation of cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) pathway and p-cAMP-response element binding protein (CREB) pathway-related protein expression is related (). The research indicated that naringenin may elevate serum levels of MTL, Gas, endothelin (ET), SP, AChE, and VIP in STC mice, while downregulating TRPV1 and NOS in colonic tissue, and upregulating the protein and mRNA levels of GDNF and BDNF. Naringenin simultaneously upregulated the expression levels of the ICCs marker proteins c-Kit and SCF ().
3.2 Terpenoids
Terpenoids refer to all isoprene polymers and their derivatives, which exhibit various biological activities, including antioxidative stress and antiviral properties (; ). Paeoniflorin is a monoterpene glycoside metabolite extracted from botanical drugs. An animal study revealed that paeoniflorin can mitigate constipation symptoms and colonic pathological damage in STC rats, enhance abnormal visceral sensitivity, potentially by elevating serum 5-HT and decreasing VIP levels, up-regulating acid-sensitive ion channel 3 (ASIC3) and phosphorylated extracellular signal-regulated kinase (p-ERK)/ERK protein and mRNA levels, and activating the ASIC3/ERK pathway (). Paeoniflorin can markedly enhance the necrosis of colonic mucosal epithelial cells and the infiltration of inflammatory cells in STC rats, while also facilitating the release of 5-HT from enterochromaffin cells, potentially through the activation of the G Protein-Coupled BA Receptor 1 (TGR5)/transient receptor potential ankyrin 1 (TRPA1) pathway (). Astragaloside IV is one of the main metabolites of Astragali radix (Astragalus membranaceus (Fisch.) Bge. var. mongholicus (Bge.) Hsiao), exhibiting many actions including the scavenging of oxygen free radicals, anti-inflammatory properties, and enhancement of cardiovascular function. A study demonstrated that astragaloside IV enhances the intestinal propulsion rate in STC mice, improves ICCs, and mitigates the loss of enterochromaffin cells by elevating the expression of CD117 and chromogranin A (CgA) proteins in colon and cecum tissues. The safeguarding of enterochromaffin cells by astragaloside IV may be facilitated through the activation of p38 and ERK pathways (). In a separate study utilizing 16S rRNA microbial analysis, astragaloside IV augmented the quantity of ICCs in the colons of STC mice and elevated the amount of Lactobacillus reuteri and butyrate synthesis. Butyrate can facilitate defecation, enhance intestinal motility, and stimulate ICCs proliferation by modulating the protein kinase B (AKT)/nuclear factor kappa-B (NF-κB) signaling pathway (). Pulsatilla saponin A is one of the metabolites from Pulsatillae radix (Pulsatilla chinensis (Bge) Regel). It can markedly augment the quantity of fecal granules, ameliorate colon pathological damage, elevate serum 5-HT levels, diminish VIP and NO levels, and upregulate c-kit and SCF protein expression in the colon tissue of STC rats. This suggests that pulsatilla saponin A may alleviate constipation symptoms in STC rats via modulating the c-kit/SCF pathway and subsequently influencing the levels of enteric neurotransmitters ().
3.3 Steroids
Steroids are a category of chemicals characterized by a cyclopentane pyranophenylene structure, exhibiting diverse biological functions including anti-inflammatory and antioxidant effects (; ). β-sitosterol is one of the metabolites of Gastrodiae rhizoma (Gastrodia elata Bl.). A study demonstrated that β-sitosterol could enhance the frequency and rate of bowel movements in STC mice, while also upregulating the mRNA and protein expression of adrenoceptor alpha 1 A (ADRA1A) and myosin regulatory light chain 9 (Myl9) in the colon, thereby facilitating intestinal peristalsis and activating the ADRA1A/myosin light chain (MLC) signaling pathway. Simultaneously, β-sitosterol can modulate serum 5-HT, AchE, and colon 5-HT4, SCF, c-Kit, and smMLCK mRNA expression to alleviate constipation symptoms (). Dioscin is one of the metabolites of Dioscoreae rhizoma (Dioscorea opposita Thunb.). It can regenerate HuC/D+ neurons in STC mice via activating the bone morphogenetic protein 2 (BMP2)/p-Smad1/5/9 signaling pathway, elevate AchE levels in colon tissue, and diminish levels of inducible nitric oxide synthase (iNOS), IL-6, and TNF-α. The microenvironment of the ENS can be enhanced, the myenteric nerve plexus can be restructured, and gastrointestinal hormone levels can be modulated to alleviate constipation (). Spicatoside A is a steroid metabolite extracted from Liriope spicata Lour. The management of STC may involve the upregulation of AChE levels and the downregulation of p-protein kinase C (PKC)/PKC and p-phosphoinositide 3-kinase (PI3K)/PI3K in colonic mucosa. Subsequent research has demonstrated that Spicatoside A can enhance the production of c-Kit and protein gene product 9.5 (PGP9.5) while reducing the levels of p-MLC/MLC in colon tissue, consequently preventing neuronal degeneration and enhancing the functionality of ICCs and SMCs ().
3.4 Polysaccharides
Polysaccharides are natural high polymers often generated by the condensation of several monosaccharide molecules with the concomitant loss of water. They possess a diverse array of biological activities and applications (). Lycium barbarum polysaccharide, mainly obtained from Lycii fructus (Lycium barbarum L.), were observed to elevate serum secretion of SP, reduce secretion of VIP, enhance expression of C-kit, SCF, and B-cell lymphoma-2 (Bcl-2), while inhibiting the expression of Bcl-2 associated X protein (Bax) and Caspase-3 in the colon tissues of STC rats. This indicates that LBP may mitigate the symptoms of STC and improve gastrointestinal peristalsis by modulating gastrointestinal hormone levels, fostering proliferation, and suppressing the apoptosis of ICCs (). Cistanche deserticola crude polysaccharide is one of the metabolites derived from the fleshy stems of the dried scaly leaves of Cistanches herba (Cistanche deserticola Y. C. Ma). One study showed that it had neuroprotective effects on STC mice. It may markedly alleviate constipation symptoms in STC mice, elevate serum SP levels, diminish VIP levels, block the degeneration of myenteric neurons, and decrease the number of nNOS+ neurons. It can diminish mitochondrial oxidative stress and dysfunction of colonic myenteric neurons by elevating superoxide dismutase (SOD) and glutathione (GSH) levels while reducing malondialdehyde (MDA) content. This regulation may be related to the upregulation of nuclear factor erythroid 2 - related factor 2 (Nrf2) and downregulation of kelch - like ECH - associated protein 1 (Keap1) protein levels, the upregulation of heme oxygenase - 1 (HO-1), NAD (P) H quinone oxidoreductase 1 (NQO1), Glutamate - cysteine ligase catalytic subunit (GCLC) and Glutamate - cysteine ligase modifier subunit (GCLM) mRNA levels, and the activation of Nrf2/Keap1 pathway ().
3.5 Anthraquinones
Anthraquinones with the parent nucleus structure of anthraquinone have a variety of pharmacological effects such as laxative, antibacterial, anti-tumor and anti-oxidation (). Emodin is one of the metabolites of Rhei radix et rhizoma (Rheum palmatum L.). A study demonstrated that emodin can decrease serum NO levels and the expression of VIP receptor 1 (VIPR1), TRPV1, and NOS in the colonic tissue of STC mice, while enhancing the expression of 5-HTR4, GDNF, BDNF, c-Kit, and SCF, thus mitigating loperamide hydrochloride-induced STC by rectifying ENS dysfunctions (). Sennoside A is the main metabolite of Sennae folium (Cassia angustifolia Vah). A study revealed that sennoside A can augment the frequency and amplitude of slow waves in ICCs within the gastrointestinal tract of STC mice by activating the HCN1 channel on the ICCs membrane. Sennoside A can elevate the concentrations of SP and motilin (MOT) in the plasma and colonic tissue of rats with STC, while concurrently decreasing levels of VIP and calcitonin gene-related peptide (CGRP), ultimately enhancing gastrointestinal peristalsis and demonstrating a beneficial therapeutic impact on STC ().
3.6 Others
Besides the aforementioned metabolites, more classes exist that potentially influence STC therapeutically by influencing essential signaling pathways. Cinnamic acid, a natural phenylpropanoid metabolite, enhances the frequency and pace of defecation in STC rats and repairs the compromised intestinal mucosa. This may pertain to the upregulation of serum 5-HT and downregulation of VIP levels, modulating the α and β variety of the intestinal microbiome, and enhancing the quantity of intestinal bacteria (). Total glucosides of paeony, derived from Paeoniae radix alba (Paeonia lactiflora Pall.), can enhance fecal volume, moisture content, and intestinal transit rate in the STC rat model. The proposed mechanism of action involves the downregulation of serum NO, NOS, and VIP, alongside the upregulation of SP content, and the enhancement of c-kit and SCF protein levels in colon tissue to ameliorate dysfunctional ICCs (). Pterostilbene is the antifungal metabolite of Draconis sanguis. It can reduce the expression of caspase-3 protein and increase the expression of c-kit and SCF protein in the colon tissue of STC rats, indicating that pterostilbene can improve the symptoms of STC constipation by reducing ICCs apoptosis and activating SCF/C-Kit pathway. Further study found that pterostilbene could reduce serum MDA and increase GSH-Px content in STC mice, and increase the protein expression of p-AKT/AKT, Nrf2 and HO-1 in colon tissue. This suggests that pterostilbeni treatment of STC is achieved by inhibiting oxidative stress through PI3K/AKT signaling mediated by its downstream Nrf2/HO-1 signaling to reduce the apoptosis of ICCs ().
4 Conclusion and prospects
In this study, 17 metabolites derived from botanical drugs were summarized, including quercetin, nobiletin, hesperidin, naringenin, paeoniflorin, astragaloside IV, pulsatilla saponin A, β-sitosterol, dioscin, spicatoside A, lycium barbarum polysaccharide, cistanche deserticola crude polysaccharides, emodin, sennoside A, cinnamic acid, total glucosides of paeony, pterostilbene. They contribute to the enhancement of STC by modulating neurotransmitter release, mending the compromised ENS, and reinstating the functions of ICCs and SMCs (Figure 1). Despite the potential of these metabolites in the prevention and treatment of STC, current research presents certain limitations: (1) The majority of research on the metabolites relies on animal studies and in vitro cellular models, with a deficiency of pertinent clinical trials to substantiate the precise efficacy of these metabolites. (2) Pan-Assay Interference Compounds (PAINS) are increasingly acknowledged by individuals. Phenols, quinones, flavonoids, steroids, and triterpenes are prevalent substances in botanical drugs, as well as in common PAINS. They have multi-target and multi-pathway therapeutic features and demonstrate effective binding to the protein active site; however, their lack of selectivity poses obstacles for drug screening. (3) Currently, pharmacological research on the metabolites of botanical drugs lacks a systematic and complete framework. Numerous research exhibit persistent and fundamental issues, necessitating comprehensive and systematic investigations across holistic, organ, cellular, and molecular dimensions. (4) Despite the potential effects of these metabolites in animal or cellular models, their toxicity and side effects remain ambiguous and require further assessment through additional animal studies and clinical trials. (5) Many metabolites exhibit inadequacies, including malabsorption and accelerated metabolism; thus, the issue of drug administration must be addressed by integrating the disease’s location or utilizing novel materials. In conclusion, metabolites from botanical drugs possess significant potential as supplementary and alternative therapies for the treatment of STC. Future research should concentrate on observing clinical efficacy, thoroughly investigating pharmacological mechanisms, and assessing drug safety and administration routes.
FIGURE 1
Statements
Author contributions
ZG: Writing – review and editing, Writing – original draft. LF: Writing – review and editing, Writing – original draft. WB: Supervision, Conceptualization, Writing – review and editing. JL: Conceptualization, Supervision, Writing – review and editing.
Funding
The author(s) declare that financial support was received for the research and/or publication of this article. This study was supported by the Jinan science and technology plan project (202225072).
Acknowledgments
Figure 1 was drawn by Figdraw.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
Abo-ZaidO. A.MoawedF. S.IsmailE. S.FarragM. A. (2023). β-sitosterol attenuates high-fat diet-induced hepatic steatosis in rats by modulating lipid metabolism, inflammation and ER stress pathway. BMC Pharmacol. and Toxicol.24 (1), 31. 10.1186/s40360-023-00671-0
2
BenskeyM. J.KuhnN. C.GalliganJ. J.GarciaJ.BoyeS. E.HauswirthW. W.et al (2015). Targeted gene delivery to the enteric nervous system using AAV: a comparison across serotypes and capsid mutants. Mol. Ther. J. Am. Soc. Gene Ther.23 (3), 488–500. 10.1038/mt.2015.7
3
BlackC. J.FordA. C. (2018). Chronic idiopathic constipation in adults: epidemiology, pathophysiology, diagnosis and clinical management. Med. J. Aust.209 (2), 86–91. 10.5694/mja18.00241
4
ChalazonitisA.RaoM. (2018). Enteric nervous system manifestations of neurodegenerative disease. Brain Res.1693 (Pt B), 207–213. 10.1016/j.brainres.2018.01.011
5
ChenF.YuY.WangP.DongY.WangT.ZuoX.et al (2014). Brain-derived neurotrophic factor accelerates gut motility in slow-transit constipation. Acta physiol. Oxf. Engl.212 (3), 226–238. 10.1111/apha.12374
6
ChenT. Y.LiM.ZhaoB.KongP. F.TangX. G. (2023). Effect of Pulsatilla saponin A on slow transit constipation in rats. Chin. J. Clin. Pharmacol.39(07), 1013–1017. Available online at: https://kns.cnki.net/kcms2/article/abstract?v=DnpHqYycDUPbTX7__OGyHrNkopZFWh7PoWx7CiizlTH5ygibTXtI7wRIOX5WAkiWgFqSIV7n0D0eE9OXc8mUNTn2VGY0t3M5fhxqrT6jU9pVE64Y5PNwqSt6cTE6AtofbgZnb0WiSdc0rteAhuTJ2-bm9Cvqb8TUYpfTlDjl61D15q-YyRwKrcdsNt2hGKwsgKIkaUAQWVPaBIAEhEJqDUoZh1XDIqDz&uniplatform=NZKPT&language=CHS.
7
ChenY.XuJ.ChenY. (2021). Regulation of neurotransmitters by the gut microbiota and effects on cognition in neurological disorders. Nutrients13 (6), 2099. 10.3390/nu13062099
8
ChuH.ZhongL.LiH.ZhangX.ZhangJ.HouX. (2014). Epidemiology characteristics of constipation for general population, pediatric population, and elderly population in China. Gastroenterology Res. Pract.2014, 532734. 10.1155/2014/532734
9
DengY.ZhaoQ.ZhouH. Y.ZhangZ. Q.ZhanY. (2024). Activation of ASIC3/ERK pathway by paeoniflorin improves intestinal fluid metabolism and visceral sensitivity in slow transit constipated rats. Kaohsiung J. Med. Sci.40 (6), 561–574. 10.1002/kjm2.12829
10
DuP.PohY. C.LimJ. L.GajendiranV.O'GradyG.BuistM. L.et al (2011). A preliminary model of gastrointestinal electromechanical coupling. IEEE Trans. bio-medical Eng.58 (12), 3491–3495. 10.1109/TBME.2011.2166155
11
GuptaS.MishraK. P.GanjuL. (2017). Broad-spectrum antiviral properties of and rographolide. Archives virology162 (3), 611–623. 10.1007/s00705-016-3166-3
12
HansenM. B. (2003). The enteric nervous system II: gastrointestinal functions. Pharmacol. and Toxicol.92 (6), 249–257. 10.1034/j.1600-0773.2003.920601.x
13
HeQ.HanC.HuangL.YangH.HuJ.ChenH.et al (2020). Astragaloside IV alleviates mouse slow transit constipation by modulating gut microbiota profile and promoting butyric acid generation. J. Cell. Mol. Med.24 (16), 9349–9361. 10.1111/jcmm.15586
14
HollandA. M.JehoulR.VrankenJ.WohlS. G.BoesmansW. (2025). MicroRNA regulation of enteric nervous system development and disease. Trends Neurosci.48 (4), 268–282. 10.1016/j.tins.2025.02.004
15
HuangL.WeiY.LiuY. L., (2023). Therapeutical effects and its mechanism of nobiletin on slow transit constipation mice. World Sci. Technology-Modernization Traditional Chin. Med.25(05), 1736–1742. Available online at: https://kns.cnki.net/kcms2/article/abstract?v=yTFySdb0ipL6W2gNs7JlN8NKeoMh2JykHenJyKsOEELVUfDi0ghzq-flIva6TmXPrYj1g3GZ8zqoGRlO5zIwzb07rwTNNiSAPx47H2GV6UgYv_sCXNIqadpxHuvcZ_TvYRxDTP3XdVGlqc44N087Ay-p8zRMiof7PPW_I-Fnrr7E0i4oVpGraN-4Zi_OtnVpLEUcDUWXds5BzuPWkTnEV-OB_zohzh2s&uniplatform=NZKPT&language=CHS.
16
HuangX.ShiY.ChenH.LeR.GongX.XuK.et al (2020). Isoliquiritigenin prevents hyperglycemia-induced renal injuries by inhibiting inflammation and oxidative stress via SIRT1-dependent mechanism. Cell death and Dis.11 (12), 1040. 10.1038/s41419-020-03260-9
17
HuizingaJ. D.HussainA.ChenJ. H. (2021). Interstitial cells of Cajal and human colon motility in health and disease. Am. J. physiology. Gastrointest. liver physiology321 (5), G552–G575. 10.1152/ajpgi.00264.2021
18
JiS. L.HanJ. R.HeL. L.ZuoZ. K. (2019). Therapeutic effect of emodin on constipation induced by loperamide in mice. Chin. J. Pathophysiol.35(12), 2262–2268. Available online at: https://kns.cnki.net/kcms2/article/abstract?v=yTFySdb0ipLHXOFAoZ91jyLTUe9owediglQuhqD7idiPPSaYklJ4EgafGE6z41nw9ONmSvTML8TAHcegujGVNQUrOzXi5uBQJPtpOHCi3nHrJ3vImQlYs0cqRdPbr1ityqWHM1dlUHXHIrdzwBHmcPSAtpB-b1HkeUzjHGcaacd9szC0nCJFlF3uQwGcjkYu-X_EQOhyF3v3RJwFDn8XvdVS5gjmG9p6&uniplatform=NZKPT&language=CHS.
19
JiY. J.FengG. Q.WangX. H.ShiL.WuG. L. (2023). A brief discussion on the therapies of TCM and Western medicine for slow-transt constipation. Chin. J. Coloproctology. 43(05), 72–74. Available online at: https://kns.cnki.net/kcms2/article/abstract?v=yTFySdb0ipLndOF1wVTirzhnvH2-F05JCNKToaIqT9cksReO-1n0-26LI49uIZlN7RToYKbWvQjWIOqOBUM51oyYy0DQN5uP5zPpDZPeyXTy_i-Eqsxgibb0yBrJBaFttAm_g4K9vxM1BaxNW2Xdbs4J56HusqYezjSV9uINqfPdT2kCTz9lhjZzwPdiBjGDVg9MX6zc3NA_84MTG1OcPI6z21PKaz90&uniplatform=NZKPT&language=CHS.
20
JiangH. Y.MaR. A.JiF. L.LiuY.WangB.FuS. Q.et al (2024). Structure characterization of polysaccharides from Cistanche deserticola and their neuroprotective effects against oxidative stress in slow transit constipation mice. Int. J. Biol. Macromol.260 (Pt 2), 129527. 10.1016/j.ijbiomac.2024.129527
21
JiangJ. G.LuoQ.LiS. S.TanT. Y.XiongK.YangT.et al (2023). Cinnamic acid regulates the intestinal microbiome and short-chain fatty acids to treat slow transit constipation. World J. Gastrointest. Pharmacol. Ther.14 (2), 4–21. 10.4292/wjgpt.v14.i2.4
22
KimJ. E.ParkJ. W.KangM. J.ChoiH. J.BaeS. J.ChoiY.et al (2019). Laxative effect of spicatoside A by cholinergic regulation of enteric nerve in loperamide-induced constipation: ICR mice model. Mol. Basel, Switz.24 (5), 896. 10.3390/molecules24050896
23
LiJ. (2019). The effect and machanism of Sennoside A on promotingintestinal motility, PLA air force medical university. Available online at: https://kns.cnki.net/kcms2/article/abstract?v=vSXt4VHTcs5fYoLfN_kDZH3RRRy4QaB5YDc5Rhd6cr4IcWiHNeMbP1cgSkaEVG1os21XLxVNNURL_9tEGMB2_-v8uqCMpW4Bg_ko-HxcF3q3MQcKIexuYq5FHt2_A6ORgx2uwAmsevYCuSzr8COUtThPM800pQqxOo9Z5qBd-qRN1jZOZJrQK2qSDRpvQurRB2J4XGRg5Tvo9i5w6JU1t5mL1EA4PNvX&uniplatform=NZKPT&language=CHS. 10.27002/d.cnki.gsjyu.2019.000273.
24
LinS. P.LiW.WintersA.LiuR.YangS. H. (2018). Artemisinin prevents glutamate-induced neuronal cell death via akt pathway activation. Front. Cell. Neurosci.12, 108. 10.3389/fncel.2018.00108
25
LiuS.ZhaoY.LiS.LiY.LiuL.ShengJ.et al (2024). Network pharmacology combined with an animal model to reveal the material basis and mechanism of Amomum villosum in alleviating constipation in mice. Gene897, 148064. 10.1016/j.gene.2023.148064
26
LiuW.ZhiA. (2021). The potential of Quercetin to protect against loperamide-induced constipation in rats. Food Sci. and Nutr.9 (6), 3297–3307. 10.1002/fsn3.2296
27
LiuY.YangB.LiuH.GuoL.LiuX. (2025). Effect and mechanism of Lycium barbarum polysaccharide on gastrointestinal motility in slow transit constipation. Naunyn-Schmiedeberg's archives Pharmacol.398 (3), 2923–2931. 10.1007/s00210-024-03446-4
28
LuJ.GuoY. S.ShiC. (2024). Research progress on sources and pharmacological activities of anthraquinones from medicinal plants. Guid. J. Traditional Chin. Med. Pharmacol.30(01), 111–116. Available online at: https://kns.cnki.net/kcms2/article/abstract?v=Kk8bzUe9ukouCslO125Cr1TrlvidvQ2Mar6rWuq2a3aH_D7N8JHRaLfds6zSaI1xUAT79g2gKtRodZHn5sO9SbMFkVCYycDz-95VscLAzQTj0r35NEFVJpL1bfEwYvk2Gvpp2ouZtYXc2w5nAiEhNjcjL4FIvQ2yylB5v6oT4w9OtYcXabYtvcTNijhYXuRnHifdFqM-O8eWkF5Xk-xewzNnYYY0bMnd&uniplatform=NZKPT&language=CHS.
29
MalekiS. J.CrespoJ. F.CabanillasB. (2019). Anti-inflammatory effects of flavonoids. Food Chem.299, 125124. 10.1016/j.foodchem.2019.125124
30
MazzoneA.StregeP. R.GibbonsS. J.AlcainoC.JoshiV.HaakA. J.et al (2020). microRNA overexpression in slow transit constipation leads to reduced NaV1.5 current and altered smooth muscle contractility. Gut69 (5), 868–876. 10.1136/gutjnl-2019-318747
31
NguyenT. T.BaumannP.TüscherO.SchickS.EndresK. (2023). The aging enteric nervous system. Int. J. Mol. Sci.24 (11), 9471. 10.3390/ijms24119471
32
RenB.FuS.LiuY.KangJ.WangB.YaoZ.et al (2022). Dioscin ameliorates slow transit constipation in mice by up-regulation of the BMP2 secreted by muscularis macrophages. Iran. J. basic Med. Sci.25 (9), 1132–1140. 10.22038/IJBMS.2022.64683.14236
33
ShiQ.HuangY.SuH.GaoY.PengX.ZhouL.et al (2019). C28 steroids from the fruiting bodies of Ganoderma resinaceum with potential anti-inflammatory activity. Phytochemistry168, 112109. 10.1016/j.phytochem.2019.112109
34
TanZ.DengJ.YeQ.ZhangZ. (2022). The antibacterial activity of natural-derived flavonoids. Curr. Top. Med. Chem.22 (12), 1009–1019. 10.2174/1568026622666220221110506
35
VlismasL. J.WuW.HoV. (2024). Idiopathic slow transit constipation: pathophysiology, diagnosis, and management. Med. Kaunas. Lith.60 (1), 108. 10.3390/medicina60010108
36
WanX.ZhouQ.ChenH.LiZ.MoM.LiuZ.et al (2023). Astragaloside IV improves slow transit constipation by regulating gut microbiota and enterochromaffin cells. Front. Pharmacol.14, 1196210. 10.3389/fphar.2023.1196210
37
WuM.LiY.GuY. (2020). Hesperidin improves colonic motility in loeramide-induced constipation rat model via 5-hydroxytryptamine 4R/cAMP signaling pathway. Digestion101 (6), 692–705. 10.1159/000501959
38
YaoZ.FuS.RenB.MaL.SunD. (2022). Based on network pharmacology and gut microbiota analysis to investigate the mechanism of the laxative effect of pterostilbene on loperamide-induced slow transit constipation in mice. Front. Pharmacol.13, 913420. 10.3389/fphar.2022.913420
39
YinJ.LiangY.WangD.YanZ.YinH.WuD.et al (2018). Naringenin induces laxative effects by upregulating the expression levels of c-Kit and SCF, as well as those of aquaporin 3 in mice with loperamide-induced constipation. Int. J. Mol. Med.41 (2), 649–658. 10.3892/ijmm.2017.3301
40
YuY.ShenM.SongQ.XieJ. (2018). Biological activities and pharmaceutical applications of polysaccharide from natural resources: a review. Carbohydr. Polym.183, 91–101. 10.1016/j.carbpol.2017.12.009
41
ZhanY.WenY.DuL. J.ShenX. L.WangX. X.WangX. F. (2023). Hesperidin improves the function of colonic SIP syncytium in rats with loperamide induced constipation. Chin. J. Integr. Traditional West. Med.43(01), 67–75. Available online at: https://kns.cnki.net/kcms2/article/abstract?v=DnpHqYycDUMwTSmHhicbE8Bxr8sRMWKGxm13H5rSS9GNev7H-us8fNqALv_bp7FPSc-DrYLM_gDu_eHP-CA1L9xGWkx1YwxuEce0oN6lsUMpE-JfVQRM5NCEek64vdzdudnG9cMkK7ui9cb22jAU8Ot9HW5HsEgKn_rs_nJ1UESjkEGUd_XREksPgdcH_V6B5ks_A5oDWumwv-VH-oIJ3C0Xp5oGb9nr&uniplatform=NZKPT&language=CHS.
42
ZhanY.WenY.ZhangL. L.ShenX. L.ChenX. H.WuX. H.et al (2021). Paeoniflorin improved constipation in the loperamide-induced rat model via TGR5/TRPA1 signaling-mediated 5-hydroxytryptamine secretion. Evidence-based complementary Altern. Med. eCAM.2021, 6076293. 10.1155/2021/6076293
43
ZhengH.LiuY. J.ChenZ. C.FanG. Q. (2021). miR-222 regulates cell growth, apoptosis, and autophagy of interstitial cells of Cajal isolated from slow transit constipation rats by targeting c-kit. Indian J. gastroenterology official J. Indian Soc. Gastroenterology40 (2), 198–208. 10.1007/s12664-020-01143-7
44
ZhouQ.HeZ.YanS.WangX.WuB. (2024). Nobiletin, an active component of Wenyang Yiqi formula, alleviates constipation associated depression through targeting MAPT to inhibit the MAPK signaling pathway. Phytomedicine Int. J. phytotherapy Phytopharm.126, 155203. 10.1016/j.phymed.2023.155203
45
ZhuF.XuS.ZhangY.ChenF.JiJ.XieG. (2016). Total glucosides of paeony promote intestinal motility in slow transit constipation rats through amelioration of interstitial cells of cajal. PloS11 (8), e0160398. 10.1371/journal.pone.0160398
Summary
Keywords
slow transit constipation, metabolites from botanical drugs, traditional Chinese medicine, pharmacological effects, ENS-ICC-SMC pathway
Citation
Gao Z, Fu L, Bai W and Liang J (2025) Protective effects of medicinal plant-derived metabolites on slow transit constipation via the ENS-ICC-SMC pathway. Front. Pharmacol. 16:1598806. doi: 10.3389/fphar.2025.1598806
Received
24 March 2025
Accepted
30 May 2025
Published
11 June 2025
Volume
16 - 2025
Edited by
Rajeev K. Singla, Sichuan University, China
Reviewed by
Xiaoyu Gao, Yunnan Agricultural University, China
Zhi Jiang, The Second Affiliated Hospital of Guanghzou University of Chinese Medicine, China
Updates
Copyright
© 2025 Gao, Fu, Bai and Liang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Wenjun Bai, xiaobei110105@163.com; Junwei Liang, sdpiwei001@126.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.